- Home
- MNDO vs KALA Comparison
MNDO vs KALA Comparison
Compare MNDO & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNDO
- KALA
- Stock Information
- Founded
- MNDO 1995
- KALA 2009
- Country
- MNDO Israel
- KALA United States
- Employees
- MNDO N/A
- KALA N/A
- Industry
- MNDO EDP Services
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- MNDO Technology
- KALA Health Care
- Exchange
- MNDO Nasdaq
- KALA Nasdaq
- Market Cap
- MNDO 24.4M
- KALA 26.2M
- IPO Year
- MNDO 2000
- KALA 2017
- Fundamental
- Price
- MNDO $1.10
- KALA $1.67
- Analyst Decision
- MNDO
- KALA Buy
- Analyst Count
- MNDO 0
- KALA 3
- Target Price
- MNDO N/A
- KALA $31.50
- AVG Volume (30 Days)
- MNDO 25.8K
- KALA 2.7M
- Earning Date
- MNDO 11-04-2025
- KALA 11-11-2025
- Dividend Yield
- MNDO 20.00%
- KALA N/A
- EPS Growth
- MNDO N/A
- KALA N/A
- EPS
- MNDO 0.15
- KALA N/A
- Revenue
- MNDO $20,155,000.00
- KALA N/A
- Revenue This Year
- MNDO N/A
- KALA N/A
- Revenue Next Year
- MNDO N/A
- KALA N/A
- P/E Ratio
- MNDO $7.40
- KALA N/A
- Revenue Growth
- MNDO N/A
- KALA N/A
- 52 Week Low
- MNDO $1.02
- KALA $1.10
- 52 Week High
- MNDO $2.13
- KALA $20.60
- Technical
- Relative Strength Index (RSI)
- MNDO 33.71
- KALA 27.87
- Support Level
- MNDO $1.10
- KALA $1.26
- Resistance Level
- MNDO $1.22
- KALA $1.69
- Average True Range (ATR)
- MNDO 0.04
- KALA 1.14
- MACD
- MNDO -0.00
- KALA -1.93
- Stochastic Oscillator
- MNDO 28.00
- KALA 2.80
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.